BiotechTube

Azithromycin microspheres 2.0 single dose

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Community-Acquired Pneumonia

Conditions

Community-Acquired Pneumonia

Trial Timeline

Sep 1, 2005 → Jun 1, 2006

NCT ID
NCT00140023

About Azithromycin microspheres 2.0 single dose

Azithromycin microspheres 2.0 single dose is a phase 3 stage product being developed by Pfizer for Community-Acquired Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00140023. Target conditions include Community-Acquired Pneumonia.

What happened to similar drugs?

1 of 7 similar drugs in Community-Acquired Pneumonia were approved

Approved (1) Terminated (0) Active (6)
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
🔄Ceftaroline + CeftriaxonePfizerPhase 3
🔄Azithromycin SRPfizerPhase 3
🔄tigecyclinePfizerPhase 3
🔄Tigecycline + LevofloxacinPfizerPhase 3
🔄Omadacycline + MoxifloxacinZai LabPhase 3
🔄ceftobiprole medocaril + IV standard-of-care cephalosporinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00140023Phase 3Completed

Competing Products

9 competing products in Community-Acquired Pneumonia

See all competitors
ProductCompanyStageHype Score
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
35
Ceftaroline + CeftriaxonePfizerPhase 3
40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
43
Azithromycin SRPfizerPhase 3
40
Azithromycin SR + AmoxiclavPfizerPre-clinical
18
tigecyclinePfizerPhase 3
40
Tigecycline + LevofloxacinPfizerPhase 3
40
Omadacycline + MoxifloxacinZai LabPhase 3
41
ceftobiprole medocaril + IV standard-of-care cephalosporinBasilea PharmaceuticaPhase 3
34